Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 5/20 | 0.57 |
| ▸ | ESRRB | O95718 | 3/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25795350 | 0.89 | ESRRG (0.46) | ESRRGESRRBNR1H4EPHX2SMN1; SMN2 | |
| SCHEMBL7223615 | 0.84 | ESRRB (0.56) | ESRRGESRRBNR1H4EPHX2THRB | |
| SCHEMBL9967846 | 0.84 | ESRRG (0.56) | ESRRGESRRBNR1H4EPHX2LMNA | |
| SCHEMBL12529918 | 0.84 | ESRRG (0.61) | ESRRGESRRBNR1H4EPHX2SMN1; SMN2 | |
| SCHEMBL27398029 | 0.81 | ESRRG (0.59) | ESRRGESRRBNR1H4SMN1; SMN2TP53 | |
| SCHEMBL16418619 | 0.81 | NR1H4 (0.53) | ESRRGESRRBNR1H4EPHX2SMN1; SMN2 | |
| SCHEMBL13024606 | 0.81 | HDAC1 (0.63) | ESRRGESRRBNR1H4SMN1; SMN2TP53 | |
| SCHEMBL4156165 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2HDAC1HTTRAB9ANPC1 | |
| SCHEMBL4402766 | 0.80 | HDAC1 (0.62) | ESRRGESRRBNR1H4EPHX2SMN1; SMN2 | |
| SCHEMBL13894647 | 0.79 | SMN1; SMN2 (0.46) | ESRRGESRRBSMN1; SMN2THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373933-A1 | SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF | TECHNODERMA MEDICINES INC (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230373933-A1 | SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF | TECHNODERMA MEDICINES INC (CN) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373933-A1 | SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF | JAK1, TYK2, JAK2 | ESRRG 4163/4885ESRRB 3620/4885NR1H4 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.